Our Services
Medical Information
Helpful Resources
Published on: 8/18/2026
Unregulated megadoses of supplements like vitamin D can flood the bloodstream with calcium (hypercalcemia), and because the kidneys must filter that excess, calcium salts crystallize and harden inside the renal tissue as nephrocalcinosis or kidney stones, while high-dose vitamin C converts into oxalate that binds calcium into the same damaging deposits. Warning signs often start quietly with excessive thirst, frequent urination, nausea, flank pain, confusion, or fatigue, and permanent scarring can occur before symptoms feel serious. Dosage thresholds, interactions, hydration status, and individual kidney function all change your personal risk, so there are several important factors to consider before assuming a supplement is safe. See below to understand the full picture, including which doses cross into toxicity and when to seek urgent care.
If you are taking high-dose supplements and noticing changes in urination, energy, digestion, or pain, a free, instant, online symptom check can help you clarify what your body is signaling and guide your next steps with confidence.
Last reviewed for medical accuracy: 08/18/2026
Unregulated megadoses of vitamin D may seem harmless or even beneficial when touted for boosting immunity or bone health. Yet taking excessive amounts can push calcium levels in the blood far beyond normal limits. This surplus calcium often ends up in the kidneys, forming crystals that lead to stones, nephrocalcinosis (calcium deposits in the kidney tissue), and even acute kidney injury. Infants are especially vulnerable; cases of vitamin D toxicity acute renal failure in infants have been documented when supplement doses far exceeded recommended levels.
Over-activation of the vitamin D pathway
• Vitamin D is converted to its active form (calcitriol) in the liver and kidneys.
• High supplemental doses drive excessive calcitriol production, which increases calcium absorption in the gut.
Hypercalcemia (too much calcium in the blood)
• Once blood calcium rises above about 10.2 mg/dL, the body struggles to maintain normal levels.
• The kidneys work harder to filter and excrete excess calcium.
Calcium precipitation in the kidneys
• When filtered calcium exceeds the solubility threshold in renal tubules, it precipitates as crystals.
• Over time, these crystals grow into stones or embed in kidney tissue (nephrocalcinosis).
• Obstructed tubules and local inflammation impair kidney function.
Early symptoms of vitamin D toxicity can be subtle. Parents and caregivers should watch for:
As calcium builds up in the kidneys, signs of acute renal failure may appear:
If you notice any of these warning signs—especially in an infant—seek medical attention immediately.
A healthcare provider will typically order the following tests:
Early diagnosis helps prevent permanent kidney damage.
Ongoing monitoring of kidney function and electrolytes ensures recovery and prevents complications.
If you suspect your child has received an unregulated or very high dose of vitamin D—especially if you observe any of the symptoms listed—do not wait. Severe hypercalcemia and acute renal failure can progress rapidly in infants.
For a free, online symptom check, using the doctor approved Ubie Symptom Checker, click here.
Always err on the side of caution. Potentially life-threatening issues require prompt medical evaluation.
If you have concerns about vitamin D dosing or any signs of kidney injury in your child, speak to a doctor without delay.
(References)
* Rhim JW. Juvenile Dermatomyositis. J Rheum Dis. 2022 Jan 1;29(1):14-21. doi: 10.4078/jrd.2022.29.1.14. PMID: 37476697; PMCID: PMC10324917.
* Lau WL, Obi Y, Kalantar-Zadeh K. Parathyroidectomy in the Management of Secondary Hyperparathyroidism. Clin J Am Soc Nephrol. 2018 Jun 7;13(6):952-961. doi: 10.2215/CJN.10390917. Epub 2018 Mar 9. PMID: 29523679; PMCID: PMC5989682.
* Gallagher JC, Rosen CJ. Vitamin D: 100 years of discoveries, yet controversy continues. Lancet Diabetes Endocrinol. 2023 May;11(5):362-374. doi: 10.1016/S2213-8587(23)00060-8. Epub 2023 Mar 30. PMID: 37004709.
* Adam MP, Bick S, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, Bali DS, El-Gharbawy A, Austin S, Pendyal S, Kishnani PS. Glycogen Storage Disease Type I. 1993. PMID: 20301489.
* Surace SJ, Deitch J, Johnston RV, Buchbinder R. Shock wave therapy for rotator cuff disease with or without calcification. Cochrane Database Syst Rev. 2020 Mar 4;3(3):CD008962. doi: 10.1002/14651858.CD008962.pub2. Epub 2020 Mar 4. PMID: 32128761; PMCID: PMC7059880.
* Greenberg RG, Lang J, Smith PB, Shekhawat P, Courtney SE, Hudak ML, Moya F, Iyengar A, Eldemerdash A, Bloom B, Go M, Hanna M, Rhein L, Aliaga S, Lewis T, Febre A, Kiefer AS, Bhatt-Mehta V, Khoury JA, Selewski D, Anand R, Martz K, Payne EH, Zimmerman KO, Benjamin DK Jr, Laughon M, Best Pharmaceuticals for Children Act – Pediatric Trials Network Steering Committee. Furosemide Safety in Preterm Infants at Risk for Bronchopulmonary Dysplasia: A Randomized Clinical Trial. J Pediatr. 2025 Aug;283:114629. doi: 10.1016/j.jpeds.2025.114629. Epub 2025 Apr 28. PMID: 40306549; PMCID: PMC12276991.
* Wu S, Luo X, Chen Y, Wang Z, Liu X, Sun N, Zhao J, Luo W, Zhang J, Tong X, Huang L, Liu C, Qin Z. Sodium-glucose cotransporter 2 inhibitors attenuate vascular calcification by suppressing endoplasmic reticulum protein thioredoxin domain containing 5 dependent osteogenic reprogramming. Redox Biol. 2024 Jul;73:103183. doi: 10.1016/j.redox.2024.103183. Epub 2024 May 13. PMID: 38759418; PMCID: PMC11127605.
* De Vriese AS, Caluwé R, Pyfferoen L, De Bacquer D, De Boeck K, Delanote J, De Surgeloose D, Van Hoenacker P, Van Vlem B, Verbeke F. Multicenter Randomized Controlled Trial of Vitamin K Antagonist Replacement by Rivaroxaban with or without Vitamin K2 in Hemodialysis Patients with Atrial Fibrillation: the Valkyrie Study. J Am Soc Nephrol. 2020 Jan;31(1):186-196. doi: 10.1681/ASN.2019060579. Epub 2019 Nov 8. PMID: 31704740; PMCID: PMC6935010.
* Dressler F, Huppertz HI. [Juvenile dermatomyositis]. Z Rheumatol. 2006 Nov;65(7):587-90, 592-4. doi: 10.1007/s00393-006-0109-5. PMID: 17051362.
* Adam MP, Bick S, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, Milliner DS, Harris PC, Sas DJ, Lieske JC. Primary Hyperoxaluria Type 3. 1993. PMID: 26401545.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.